Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction

Labos, Christopher; Dasgupta, Kaberi; Nedjar, Hacene; Turecki, Gustavo; Rahme, Elham
November 2011
CMAJ: Canadian Medical Association Journal;11/8/2011, Vol. 183 Issue 16, p1835
Academic Journal
Background: Pa tients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake inhibitor (SSRI) to treat coexisting depression. Use of either treatment may in crease the risk of bleeding. We assessed the risk of bleeding among patients taking both medications following acute myocardial infarction. Methods: We conducted a retrospective co hort study using hospital discharge abstracts, physician billing information, medication re imbursement claims and demographic data from pro - vincial health services administrative databases. We in cluded patients 50 years of age or older who were discharged from hospital with anti -platelet therapy following acute myocardial infarction be tween January 1998 and March 2007. Patients were followed until admission to hospital due to a bleeding episode, admission to hospital due to recurrent acute myocardial infarction, death or the end of the study period. Results: The 27 058 patients in the cohort received the following medications at discharge: acetylsalicylic acid (ASA) (n = 14 426); clopidogrel (n = 2467), ASA and clopidogrel (n = 9475); ASA and an SSRI (n = 406); ASA, clopidogrel and an SSRI (n = 239); or clopidogrel and an SSRI (n = 45). Compared with ASA use alone, the combined use of an SSRI with antiplatelet therapy was associated with an increased risk of bleeding (ASA and SSRI: hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.08-1.87; ASA, clopidogrel and SSRI: HR 2.35, 95% CI 1.61-3.42). Compared with dual antiplatelet therapy alone (ASA and clopidogrel), combined use of an SSRI and dual antiplatelet therapy was associated with an increased risk of bleeding (HR 1.57, 95% CI 1.07-2.32). Interpretation: Patients taking an SSRI together with ASA or dual antiplatelet therapy following acute myocardial infarction were at increased risk of bleeding.


Related Articles

  • Non-cardiac surgery in patients with coronary stents: the RECO study. Albaladejo, Pierre; Marret, Emmanuel; Samama, Charles-Marc; Collet, Jean-Philippe; Abhay, Kou; Loutrel, Olivier; Charbonneau, Hélène; Jaber, Samir; Thoret, Sophie; Bosson, Jean-Luc; Piriou, Vincent // Heart;Oct2011, Vol. 97 Issue 19, p1566 

    Context Interruption or maintenance of oral antiplatelet therapy (OAT) during an invasive procedure may result in ischaemic and/or haemorrhagic complications. There is currently a lack of clear guidance regarding the issue of treatment interruption during surgical procedures. Objective To...

  • DAPT Study. Zarifyan, Alla; Mauri, Laura // MD Conference Express;Oct2015, Vol. 15 Issue 28, p19 

    An analysis of mortality in the DAPT study revealed that although there was a borderline increase in mortality in the continued thienopyridine arm, it was mainly related to non-cardiovascular deaths, and bleeding accounted for a minority of these deaths. Although cancer-related deaths were...

  • Anti-Platelet Therapy. Smyth, Susan S. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1790 

    No abstract available.

  • Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. Seung-Jung Park; Park, Duk-Woo; Young-Hak Kim; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Ki-Hoon Han; Seong-Wook Park; Sung-Cheol Yun; Sang-Gon Lee; Seung-Woon Rha; In-Whan Seong; Myung-Ho Jeong; Seung-Ho Hur; Nae-Hee Lee; Junghan Yoon; Joo-Young Yang; Bong-Ki Lee; Young-Jin Choi; Wook-Sung Chung // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1374 

    Background: The potential benefits and risks of the use of dual antiplatelet therapy beyond a 12-month period in patients receiving drug-eluting stents have not been clearly established. Methods: In two trials, we randomly assigned a total of 2701 patients who had received drug-eluting stents...

  • AIDA STEMI: Direct administration of abciximab no more effective than IV delivery. Fisher, Stacey L.; Foster, Melissa; Kalvaitis, Katie; Murphy, Casey // Cardiology Today;Jan2012, Vol. 15 Issue 1, p19 

    The article focuses on a study which examined the effectiveness of direct administration of platelet inhibitor abciximab in improving overall health outcomes in patients with severe myocardial infarction.

  • Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. Palmer, Suetonia C.; Micco, Lucia Di; Razavian, Mona; Craig, Jonathan C.; Perkovic, Vlado; Pellegrini, Fabio; Copetti, Massimiliano; Graziano, Giusi; Tognoni, Gianni; Jardine, Meg; Webster, Angela; Nicolucci, Antonio; Zoungas, Sophia; Strippoli, Giovanni F. M. // Annals of Internal Medicine;3/20/2012, Vol. 156 Issue 6, p445 

    Background: Antiplatelet agents are used to prevent cardiovascular events; however, treatment effects may differ in persons with chronic kidney disease (CKD) because atherosclerotic disease is less prevalent, whereas bleeding hazards may be increased in this population. Purpose: To summarize the...

  • Optimal length of dual therapy is still unclear.  // BMJ: British Medical Journal;5/30/2015, Vol. 350 Issue 8010, p2841 

    The article discusses a study published in the journal "Annals of Internal Medicine" reveals the association between longer duration of dual antiplatelet therapy and fewer myocardial infarctions but more bleeding than treating for a shorter period.

  • Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction. Eyuboglu, Mehmet // Cardiovascular Drugs & Therapy;Oct2015, Vol. 29 Issue 5, p495 

    A letter to the editor is presented in response to the article "Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients With Myocardial Infarction," that was published in the previous issue.

  • What is the cause of the guideline prescribing gap post myocardial infarction? Wilkins, B.; Hullikunte, S.; Simmonds, M.; Harding, S.; Larsen, P. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS397 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics